Recruitment unclearEUCTR 2007-007538-21
A Multi-center, Inpatient and ambulatory, Phase 2, Double-blind, Randomised, Placebo-controlled Proof of Concept Study of CYR-101 in Patients with DSM-IV Schizophrenia
This historical record does not confirm current site availability.
Historical research recordFrance
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who could participate?
This study is for people with schizophrenia. Other eligibility criteria apply.
- Listed locations
- France
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Recruitment unclear
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- CYRENAIC
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- France
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2007-007538-21
- Official title
Show the full official title
A Multi-center, Inpatient and ambulatory, Phase 2, Double-blind, Randomised, Placebo-controlled Proof of Concept Study of CYR-101 in Patients with DSM-IV Schizophrenia
Recruitment & locations
Status unknownThis badge reflects the study status reported by the registry. Check the registry for the latest information.
France
Registry details
Historical country statuses
- France — Ongoing
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is CYRENAIC.
Who can participate?
This study is for people with schizophrenia. Other eligibility criteria apply.
Want to explore more studies?
Explore studiesRelated studies
A 104-WEEK, FLEXIBLE-DOSE, OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFECTIVENESS OF LURASIDONE IN PEDIATRIC SUBJECTS WITH SCHIZOPHRENIA AND SUBJECTS WITH IRRIT...
A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis